Claims for Patent: 10,488,413

Summary for Patent: 10,488,413

Title:	Methods for treating patients at risk for costimulation blockade resistant rejection with belatacept
Abstract:	The present invention provides methods utilizing changes in CD4+CD57+ T cells levels for determining the susceptibility of a transplant patient or patient in need thereof to costimulation blockade resistant rejection. These methods are useful for identifying effective drug regimens for the treatment of immune disorders associated with graft transplantation and/or maintenance of a transplant.
Inventor(s):	Kirk; Allan D (Durham, NC), Espinosa; Jaclyn Rae (Durham, NC), Townsend; Robert M (Garnet Valley, PA)
Assignee:	BRISTOL-MYERS SQUIBB COMPANY (Princeton, NJ)
Application Number:	15/659,196
Patent Claims:	1. A method of treating a transplant patient at risk of costimulation blockade therapy rejection, the method comprising: (a) providing a transplant patient or a patient in need of a transplant having at least a 2-fold increase in CD4+CD57+T cells as compared to a normal healthy control; and (b) administering belatacept to the transplant patient wherein belatacept is administered to the transplant patient pursuant to an early phase regimen and a maintenance phase regimen; wherein the early phase regimen comprises administering 10 mg/kg of belatacept to the transplant patient during the first three to six months post-transplantation; and wherein the maintenance phase regimen comprises administering 5 mg/kg of belatacept monthly to the transplant patient following the early phase regimen and continuing for the life of the transplant. 2. The method according to claim 1, wherein the early phase regimen comprises administering belatacept on the day of the transplant, about 96 hours post-transplant, two weeks post-transplant, four weeks post-transplant, eight weeks post-transplant and twelve weeks post-transplant. 3. The method according to claim 2, further comprising administering belatacept sixteen weeks post-transplant, twenty weeks post-transplant and twenty-four weeks post-transplant. 4. The method according to claim 1, wherein the transplant comprises solid organ, tissue and/or cell. 5. The method according to claim 4, wherein the transplant comprises skin, islet cells, muscles, hepatocytes, neurons, heart, liver, kidney, lung, appendages, limbs, nose, ear or face. 6. The method according to claim 4, wherein the transplant is a kidney.

Details for Patent 10,488,413

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	NULOJIX	belatacept	For Injection	125288	06/15/2011		2033-03-28